Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech’s stock pops 20%

Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to ...

2 New Oncology Focused Small-Cap Biotechs to Keep an Eye On

The biotech sector has held up better than one would expect during the carnage and volatility in the markets over the past couple of months. The lows this sector made in mid-June have formed a firm fl...